| Similar Articles |
|---|
 |
The Motley Fool
November 17, 2006
Jack Uldrich |
Neanderthal DNA Enlightens Investors Investors, the superb performance of 454's gene sequencing equipment on such a difficult and important project bodes well for its future prospects.   |
The Motley Fool
March 30, 2007
Ralph Casale |
Another Genetic Sequencer Gobbled Up Roche buys out second-generation sequencer 454 Life Sciences. Investors, take note. |
Bio-IT World
April 2007 |
News Briefs Molecular Medicine's "Best of Show"... Dissolving Assets... Combined Forces... |
Bio-IT World
October 2005
Dennis A. Gilbert |
The DNA Sequencing Race: From Sprint to Marathon To create faster, cheaper, and better solutions for DNA analysis, we must remain committed to improving both current and new sequencing technologies. Research that just a short while ago might have been considered too complex, too expensive, or just inconceivable is now well within our grasp. |
The Motley Fool
August 12, 2009
Brian Orelli |
The Next Big Thing Is Not Right in Front of You Perhaps the fastest evolving technology right now is found in DNA sequencing. |
The Motley Fool
March 17, 2011
Brian Orelli |
Eat or Be Eaten? Perhaps Both. Oft-rumored takeout target Human Genome Sciences goes shopping. |
Bio-IT World
November 14, 2003
Julia Boguslavsky |
Genome Center in a Box Scientists at 454 Life Sciences developed an integrated end-to-end instrument that performs hundreds of thousands of reactions in parallel -- from sample preparation, amplification, and sequencing to data storage and bioinformatics. |
The Motley Fool
January 14, 2010
Brian Orelli |
$1,000 Genomes, Here We Come Illumina jumps on news of its $10,000 genome. |
The Motley Fool
August 18, 2010
Luke Timmerman |
Life Technologies Competes for Cheap DNA Sequencing In the race to cheaper gene sequencing. |
HHMI Bulletin
May 2012
Sarah C. P. Williams |
Opening the Floodgates Researchers are using exome sequencing -- zeroing in on the genes that encode proteins -- to explore the biology of certain diseases. |
IEEE Spectrum
March 2013
Susan Hassler |
Genome to Go It's already possible to have your own genome sequenced. But personalized medicine based on sequencing still has a way to go |
Bio-IT World
September 2005
Kevin Davies |
Fantastic 454: DNA Sequencing Pyrotechnics In an exciting advance for DNA sequencing technology, a research team at 454 Life Sciences Corp. has essentially sequenced and assembled a bacterial genome sequence based on a mere 4-hour run on the company's proprietary instrument. |
IEEE Spectrum
March 2013
Eliza Strickland |
The Gene Machine and Me Ion Torrent's chip-based genome sequencer is cheap, fast, and poised to revolutionize medicine |
BusinessWeek
November 6, 2006
Gene G. Marcial |
Solexa's Progress Is In The Genes New technology makes Solexa a leading contender in the next-generation sequencing race. |
Popular Mechanics
April 25, 2008
Erik Sofge |
Inside the Forgotten X Prize--the One That Can Save Your Life An extensive look at the Archon X Prize in Genomics, the $10 million race for a cheap, disease-hunting gene sequencer that could land on your kitchen counter sooner than you think. |
Chemistry World
May 29, 2014
Hepeng Jia |
Chinese-made DNA sequencer aims to challenge foreign dominance With an independently developed next-generation DNA sequencer, Chinese scientists are aiming to challenge the dominance of international players in the world's fastest growing genome sequencing market. |
Fast Company
November 2009
David H. Freedman |
The Gene Bubble: Why We Still Aren't Disease-Free When the human genome was first sequenced nearly a decade ago, the world lit up with talk about how new gene-specific drugs would help us cheat death. Well, the verdict is in: Keep eating those greens. |
Bio-IT World
October 9, 2002
Kevin Davies |
Cracking the 'Druggable Genome' How many potential drug targets are encoded in the human genome? It is a crucial question for every biopharma business. |
Bio-IT World
February 2006
Kevin Davies |
Solexa Readies 1G Genetic Analyzer Solexa, one of the firms vying to crack the $1,000 genome threshold, has officially launched its first commercial genome sequencing instrument. |
BusinessWeek
October 23, 2008
John Carey |
Reading the Entire Genetic Code Pioneers such as 23andMe and Navigenics use snips of genes to make medical predictions. Now new tools from more start-ups are on the horizon. |
The Motley Fool
October 26, 2011
Brian Orelli |
Down 20%: Benylsta Not Ramping Fast Enough Sales of Human Genome Sciences' new lupus drug Benylsta continues to grow -- just not fast enough to keep investors interest. |
Bio-IT World
August 13, 2003
Michael Greeley |
Two Cents on the '$1,000 Genome' Are venture capitalists still looking for 'the killer app'? Funding the next big idea won't be so easy. Affordable, individualized genome sequencing holds great promise, but making the claims sound too grandiose can be dangerous. |
Salon.com
June 27, 2000
Tabitha M. Powledge |
Book of life? Hosanna! The Human Genome Project has been completed. We will now cure diseases, weed out defective genes and create a new supergeneration in the near future. Not. |
Pharmaceutical Executive
October 1, 2011
Jill Wechsler |
Guiding a Revolution in Science Francis Collins led the genomic revolution as director of the International Human Genome Project and director of the National Human Genome Research Institute (NHGRI) at the NIH from 1993 to 2008. |
BusinessWeek
June 13, 2005
John Carey |
The NIH's Roadmap for Research Charting the human genome was just the beginning. Now the focus is creating pathways that will lead to practical applications. |
Fast Company
September 2000
John Ellis |
The Secret of Life The mapping of the human genome, says Craig Venter, will change science, research, medicine, politics, health insurance, and the way biology looks at the last 3 billion years of evolution. And that's just the beginning. |
Salon.com
February 13, 2001
Arthur Allen |
Size doesn't matter As scientists unveil the human genome findings, it turns out we have a lot fewer genes than we'd thought, and not many more than a fruit fly... |
Wired
August 2000
Jennifer Hillner |
Area 22 The inside story of the first fully sequenced chromosome. |
The Motley Fool
December 14, 2004
Charly Travers |
Genetics of a Rule Breaker Investing is a lifelong learning process. We never know everything, but it is important we strive to learn from the lumps we take along the way. Here are some hard-earned tips from a biotech investor. |
Salon.com
May 1, 2000
Arthur Allen |
Listening to DNA The genome project is getting the buzz. But the real breakthroughs may come from labs out of the limelight, like Gene Logic. |
BusinessWeek
May 9, 2005
John Carey |
Dr. Francis S. Collins: On The Trail Of Disease Genes Collins is leading the search for DNA variations that can result in illnesses. |
The Motley Fool
August 18, 2010
Travers & Jayson |
The Most Important Thing About Human Genome Sciences Is Human Genome Sciences on strong financial footing? Take a look. |
HHMI Bulletin
May 2012
Sarah C. P. Williams |
Stephen Quake: Innovative Thinking on Genetic Tests His ideas have already led to a blood test to tell a pregnant woman whether her fetus has Down syndrome. Now, the HHMI investigator is pushing further, to track the success of heart transplants and diagnose autoimmune diseases and allergies. |
The Motley Fool
March 26, 2004
Charly Travers |
Human Genome Getting on Track What a novel concept for a drug company to focus on commercializing drugs. |
Bio-IT World
November 12, 2002
Davies et al. |
John Craig Venter Unvarnished The former Celera CEO talks about that company's politics, the future of sequencing technology, and his own genome. |
Information Today
August 4, 2011 |
Elsevier Introduces Genome Viewer The Genome Viewer is a SciVerse application that displays detailed gene or genomic sequence information on the genes mentioned in an article. |
The Motley Fool
November 17, 2010
Brian Orelli |
52 Years Down, 1 Month to Go Lupus treatment Benlysta moves closer to approval. |
Chemistry World
January 27, 2012
Sarah Houlton |
Illumina fends off Roche hostile bid Roche has made a $5.7 billion hostile bid for the genome sequencing company Illumina, after the San Diego, US-based company rejected its initial approach. |
Bio-IT World
Dec 2006/Jan 2007
Kevin Davies |
The One Percent Difference New research reveals a shocking new layer of human genome variation with profound implications for the future of genomic analysis and personalized medicine. |
The Motley Fool
February 28, 2008
Brian Lawler |
Too Much Hope in Human Genome Shares Human Genome announces its guidance for 2008. Investors, take note. |
Bio-IT World
December 10, 2002 |
Craig Venter Unvarnished (part II) The former Celera CEO covers privacy, ESTs, and his new research institutes. |
The Motley Fool
May 28, 2010
Brian Orelli |
Is It Time to Make Money Investing in Genetic Testing? Easier said than done. |
Bio-IT World
Jul/Aug 2006
Kate McDonald |
The Next Generation in Sequencing Is SOLiD Applied Biosystems has completed the acquisition of genetic analysis company Agencourt Personal Genomics for $120 million, and hopes to bring the company's novel next-generation sequencing technology to market next year. |
Bio-IT World
April 2006
Karen Hopkin |
AGBT Meeting Puts Genome Advances Front and Center If the presentations at February's Advances in Genome Biology and Technology (AGBT) are any indication, the race to generate fresh approaches to produce more sequence for less is far from over -- and looks to be heating up. |
Wired
November 17, 2007
Thomas Goetz |
23AndMe Will Decode Your DNA for $1,000. Welcome to the Age of Genomics A much-anticipated Silicon Valley startup called 23andMe offers a thorough tour of your genealogy, tracing your DNA back through the eons. |
Managed Care
August 2004
Thomas Morrow |
10,000 Cells on a Chip Signal Start of New Era of Diagnosis Diseases will soon be defined by biochemical pathways and genetic interactions. Biochips may identify patients likely to respond to therapeutic agents. All of this is a big deal for health plans. |
Chemistry World
August 22, 2014
Phillip Broadwith |
Illumina targets cancer diagnostics Genetic sequencing heavyweight Illumina has partnered with three major pharmaceutical firms in a bid to develop a universal sequencing-based oncology test system. |
Bio-IT World
July 14, 2004
Malorye A. Branca |
The Maven of Microarrays Affymetrix Research Institute's CEO, Stephen Fodor, discusses building a tech business without a blueprint |
Bio-IT World
May 2006
Kevin Davies |
Interpreting Genes and Genomes From microarrays to sequencing technology, molecular diagnostics to the interactome, this year's Bio-IT World Conference showcased exciting advances in genome technology applications, in which software analysis and data management play critical roles. |
Chemistry World
July 13, 2011
Hayley Birch |
Naked mole-rat genome holds clue to beating cancer The recently published draft sequence of the naked mole-rat genome promises to reveal the secrets of its long and remarkably cancer-free existence, potentially providing new targets for anti-cancer drugs. |
